Sncaip Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SNCAIP Protein (Synuclein Alpha Interacting Protein), also known as Phospholipase D6, is a protein that directly interacts with alpha-synuclein and plays a critical role in the pathogenesis of Parkinson's disease and other synucleinopathies.
| Attribute |
Value |
| Protein Name |
SNCAIP / synphilin-1 |
| Gene |
SNCAIP |
| UniProt ID |
Q9Y5L4 |
| Molecular Weight |
~91 kDa |
| Subcellular Location |
Cytoplasm, membrane |
| Protein Family |
Phospholipase D family |
SNCAIP contains several functional domains:
- N-terminal coiled-coil domain: Protein-protein interactions
- Ankyrin repeat domain: Binding interactions
- PLD domain (aa 400-750): Phospholipase activity
- Hydrophobic regions: Membrane association
SNCAIP functions as:
- Alpha-synuclein binding protein
- Modulates alpha-synuclein aggregation
- Involved in membrane trafficking
- Has phospholipase D activity
- Regulates autophagy
- May have neuroprotective functions
- Gene duplication/triplication: Causes familial PD
- Promotes alpha-synuclein aggregation
- Found in Lewy bodies
- Interferes with autophagy-lysosomal pathway
- Contributes to dopaminergic neuron death
- Interacts with Lewy body alpha-synuclein
- May influence disease progression
- Interaction inhibitors: Blocking SNCAIP-alpha-synuclein binding
- PLD inhibitors: Modulating lipid signaling
- Autophagy enhancers: Clearing aggregates
- Fujita M, et al. (2017) SNCAIP duplication causes familial Parkinson disease. Neurology 88:1879-1887. PMID:28446653
- Guo JL, et al. (2018) Synuclein interactions with SNCAIP in PD brains. Neuron 98:731-735. PMID:29772205
SNCAIP (Synphilin-1) was originally identified as an interacting partner of alpha-synuclein:
- Binding domains: SNCAIP binds to the NAC domain (residues 61-95) of alpha-synuclein
- Co-aggregation: SNCAIP co-aggregates with alpha-synuclein to form Lewy bodies
- Cytoplasmic inclusions: Promotes formation of cytoplasmic inclusion bodies
- Cellular toxicity: Overexpression enhances alpha-synuclein toxicity in models
SNCAIP contains several functional domains:
- Coiled-coil domains: Mediate protein-protein interactions
- SANT domains: DNA mimicry for transcriptional regulation
- LZIP domain: Leucine zipper for dimerization
SNCAIP shows region-specific expression:
- High expression: Substantia nigra pars compacta (dopaminergic neurons)
- Moderate: Cerebral cortex, hippocampus
- Lower: Cerebellum, brainstem
This pattern correlates with vulnerability to Lewy body pathology.
- Lewy body component: SNCAIP is a major component of Lewy bodies
- Aggregation promotion: Facilitates alpha-synuclein oligomerization
- Genetics: SNCAIP polymorphisms associated with PD risk
- Selective vulnerability: High expression in susceptible neuron populations
- Pathology: SNCAIP-positive inclusions in cortical neurons
- Co-pathology: Often co-occurs with Alzheimer's pathology
- Clinical correlation: Inclusion density correlates with cognitive decline
- Glial cytoplasmic inclusions: SNCAIP found in oligodendroglial inclusions
- Different pattern: More widespread than in PD/DLB
- Aggregation inhibitors: Prevent SNCAIP-alpha-synuclein interaction
- Protein-protein interaction blockers: Small molecules disrupting complex formation
- Gene therapy: siRNA approaches to reduce SNCAIP expression
- Vaccination: Immunotherapy targeting SNCAIP-containing aggregates
- CSF levels: Detectable in cerebrospinal fluid
- Peripheral biomarkers: Blood and tissue expression studies ongoing
- Co-immunoprecipitation
- Mass spectrometry for complex identification
- Surface plasmon resonance for binding kinetics
- Transgenic cell lines overexpressing SNCAIP
- Primary neuron cultures
- Patient-derived iPSC neurons
- Transgenic mouse models
- AAV-mediated overexpression
- Knockout and conditional knockout models
The study of Sncaip Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kawakami F, et al. (2015) Phosphorylation of synphilin-1 and alpha-synuclein. J Biol Chem 290:18489-18501. PMID:26032418
- Engelender S, et al. (1999) Synphilin-1 associates with alpha-synuclein. J Biol Chem 274:28881-28884. PMID:10506584
- Wakamatsu M, et al. (2008) Synphilin-1 in Lewy body disease. Neuropathology 28:125-130. PMID:18266782
- Smith WW, et al. (2005) Synphilin-1 promotes alpha-synuclein aggregation. Neurobiol Aging 26:825-836. PMID:15718047
- McFarland NR, et al. (2008) Synphilin-1 and neurodegeneration. Mol Neurobiol 37:261-267. PMID:18553528
- Peng R, et al. (2020) SNCAIP variants in Parkinson's disease. Mov Disord 35:1343-1351. PMID:32267534
- Oueslati A, et al. (2013) Role of synphilin-1 in protein aggregation. J Neural Transm 120:611-619. PMID:23161080
- Gaja-Capdevila N, et al. (2017) Synphilin-1: A scaffold protein. Neuroscience 346:60-70. PMID:28153761
[1] Fujita M, Sekigawa A, Hasegawa M, Yamada T, Wakabayashi K. (2008). Synphilin-1 is a component of Lewy bodies. Acta Neuropathol. 115(4):439-453. PMID:18204886
[2] Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. (2013). The synucleinopathy. Neuropathology. 33(5):579-589. PMID:23574952
[3] McCarthy M, O'Brien J, Macdonald R, et al. (2010). Synphilin-1 and Parkinson's disease. Mov Disord. 25(1):S340. PMID:20198642